Primary safety outcomes | 5 mg | 10 mg | 15 mg | Overall |
---|---|---|---|---|
All adverse events | 1.04 (1.00, 1.09) P ≥ 0.05 | 1.07 (1.03, 1.11) P < 0.05 | 1.10 (1.07, 1.14) P < 0.05 | 1.07 (1.05, 1.10) P < 0.05 |
Serious adverse events | 1.04 (0.97, 1.10) P ≥ 0.05 | 1.02 (0.98, 1.05) P ≥ 0.05 | 0.99 (0.95, 1.02) P ≥ 0.05 | 1.01 (0.99, 1.03) P ≥ 0.05 |
Hypoglycemic events | 0.75 (0.69, 0.81) P < 0.05 | 0.93 (0.89, 0.98) P < 0.05 | 0.75 (0.69, 0.81) P < 0.05 | 0.89 (0.87, 0.92) P < 0.05 |
Gastrointestinal events | 1.078 (0.965, 1.203) P ≥ 0.05 | 1.262 (1.138, 1.400) P < 0.05 | 1.296 (1.172, 1.432) P < 0.05 | 1.213 (1.142, 1.289) P < 0.05 |
Discontinuation of therapy | 1.22 (1.12, 1.33) P < 0.05 | 1.13 (1.07, 1.19) P < 0.05 | 1.15 (1.09, 1.21) P < 0.05 | 1.15 (1.12, 1.19) P < 0.05 |
Fatal adverse events | 1.04 (0.98, 1.09) P ≥ 0.05 | 0.98 (0.96, 1.00) P ≥ 0.05 | 1.00 (0.97, 1.02) P ≥ 0.05 | 1.00 (0.98, 1.01) P ≥ 0.05 |
Decreased appetite | 3.213 (1.423, 7.256) P < 0.05 | 2.963 (1.153, 7.612) P < 0.05 | 1.12 (1.06, 1.19) P < 0.05 | 3.021 (1.863, 4.901) P < 0.05 |